top of page
  • Amazon
  • Youtube
  • TikTok
  • Facebook
  • Instagram
Copy of kindle cover.jpg

WE'RE BUILDING A FIRST OF ITS KIND OBESITY MEDICINE NEWS PLATFORM

SIGN UP FOR FREE HERE TO GET DAILY UPDATES FROM ON THE PEN! NEVER MISS A HEADLINE!

Search

Eli Lilly CAN Sue Against "Personalized" Medicine Ads, Judge Rules

Where does this leave GLP-1 Compounding?

Original posted at obesity.news/ on Sep 02, 2025


Yesterday, September 24, Judge Jon Tigar of the Northern District of California issued a ruling in Eli Lilly v. Adonis Health (Henry Meds). The decision matters far beyond Henry, because Lilly is fighting nearly identical battles against other telehealth platforms, including Mochi Health. This decision cuts right to the very heart of how compounded GLP-1 medications are currently advertised and sold.


ree

Here’s what the court said:


  • Lilly has the right to sue over false advertising when companies claim their compounded tirzepatide is “personalized,” “tailored,” or “patient-specific.” Judge Tigar found those kinds of claims could mislead patients and allowed that part of the case to move forward.


  • The judge tossed out Lilly’s argument that Henry falsely advertised its drugs as “safe and effective.” The court said Lilly was really just pointing to a lack of scientific proof, not proving the statements were flat-out false.

ree

So where does this leave us? It is a split decision, but on the most important question, whether “personalization” claims can be challenged as false advertising, Lilly won.


Fast forward to today: in Lilly’s lawsuit against Mochi Health, the company just asked Judge Jacqueline Scott Corley for permission to file this fresh ruling. Why? Because Mochi made very similar arguments to the ones Henry did. If Judge Corley considers Judge Tigar’s reasoning, Mochi’s chances of dodging Lilly’s lawsuit drop dramatically.


⚖️ Translation: Lilly is building momentum. Henry Meds could not knock Lilly out. Mochi may not be able to either.


Stay tuned to all of our socials for more updates and in-depth analysis on the latest developments in weight loss and diabetes treatments. Sharing this article is a powerful form of advocacy that brings us closer to our goal of educating the masses and reducing the stigma of obesity. If you found this article insightful, please share it within your networks, especially in Facebook groups and Reddit forums dedicated to GLP-1 medications and diabetes management. Together, we can make a difference.


This Substack is reader-supported.

To receive new posts and support my work,

consider becoming a free or paid subscriber.




bottom of page